Visual Design Co-op

MegazoneCloud begins building Hanmi Pharmaceutical's quality assurance AI agent with 'AIR Studio' By PR Newswire September 11, 2026 Fine-tunes the Korean model Solar and deploys it on its own AI platform, AIR Studio, to automate quality-document operations Part of the MSIT - NIPA 'AX One-Stop Voucher Program'; consortium formed with Hanmi Pharmaceutical, Samsung SDS, and Selectstar SEOUL, South Korea, Sept. 11, 2026 /PRNewswire/ - MegazoneCloud (CEO Doug Yeum), a leading AI and cloud company, is undertaking the development of 'Hanmi Q-Agent,' an AI agent that automates Hanmi Pharmaceutical's quality assurance (QA) operations, based on its enterprise AI OS 'AIR Studio.' Hanmi Q-Agent is an AI agent that supports the retrieval and analysis of vast quality documents. MegazoneCloud, which is responsible for implementing the AI solution for this project - part of the 'AX One-Stop Voucher Program,' through which the Ministry of Science and ICT (MSIT) and the National IT Industry Promotion Agency (NIPA) provide integrated support for AI, cloud, and data in voucher form - began system development on the 7th. MegazoneCloud will build the search-based AI agent for some 4,000 quality documents accumulated by Hanmi Pharmaceutical. Applying its in-house enterprise AI OS 'AIR Studio,' the company will implement a RAG (retrieval-augmented generation)-based agent that retrieves and summarizes these documents and compares them against the latest regulations. The goal is to identify and correct items that do not conform to newly added or revised regulations, thereby reducing related work time by more than 40%. Quality documents are prepared and managed to demonstrate that pharmaceuticals have been manufactured consistently and in accordance with regulations; they contain a mix of tables, figures, and formulas, with Korean and English notation used side by side. Until now, staff have had to search through vast volumes of documents themselves and manually cross-check them against the latest regulatory standards and internal guidelines. In particular, discrepancies with regulations have mostly been corrected only after inspections. Once the system is in place, preventive quality management that reflects the latest regulations in real time is expected to become possible. As the engine that generates Hanmi Q-Agent's responses, MegazoneCloud fine-tunes Upstage's Korean model 'Solar' to Hanmi Pharmaceutical's GMP domain and deploys it on the AIR Studio-based agent. GMP (Good Manufacturing Practice) is an international standard for manufacturing pharmaceuticals at a consistent level of quality and is central to pharmaceutical quality assurance operations. Suh Min-taek, Vice President of MegazoneCloud, said, "The pharmaceutical quality field is one of the most demanding areas for AI adoption, as a single word can determine a regulatory judgment and the requirements for accuracy and traceability are exceptionally strict." He added, "Having proven our AIR Studio and fine-tuning capabilities through generative-AI implementations across a range of industries, such as Hanatour's AI chat consultation service, we will lead the expansion of domain-specific AI in regulated industries through this project." In the Hanmi Q-Agent project, Hanmi Pharmaceutical serves as the overall lead, while MegazoneCloud handles AI solution implementation and fine-tuning, Samsung SDS provides the AX infrastructure, and Selectstar performs data processing and third-party verification. The four companies held the "2026 AX One-Stop Voucher Program Hanmi Pharmaceutical Consortium Kickoff" on August 28. About MegazoneCloud MegazoneCloud is a leading AI and cloud-native company with some 2,000 AI and cloud experts, serving as an enterprise AI orchestrator that supports the AI transformation (AX) and business innovation of more than 8,000 customers in Korea and abroad. Built on partnerships with major global and domestic CSPs and an ecosystem of over 200 ISV partners, together with its own cloud, AI, data, and security solutions, the company provides end-to-end services - from AI strategy and data development to infrastructure modernization and the development and operation of AI models and AI agents - enabling enterprises to operate complex AI environments effectively and create business results in the multi-agent era. Under its vision "Transform Tomorrow, Together," MegazoneCloud is establishing itself as a strategic partner for customers' AI innovation and growth across 10 countries, including Korea, North America, Japan, Southeast Asia, Oceania, and the Middle East.

Megazone Cloud, an AI and cloud computing company, has secured a pre-IPO investment from Neowiz Partners through an unconditional purchase of common shares. The company plans to use the funds to develop future growth engines including AI and security. Megazone Cloud previously raised significant funding rounds: ₩48 billion in Series A (2019), ₩190 billion across two Series B rounds (2020-2021), ₩130 billion from strategic investor KT (2022), and ₩450 billion in Series C. In June, parent company Megazone received ₩800 billion from Glenwood Credit, using it to acquire existing stakes and increase its holding to 72%. CEO Yeom Dong-hoon said the investment recognises the company's growth potential and future value. Neowiz Partners CEO Kim Sang-wook cited Megazone Cloud's competitive position in AI and cloud business as key to the investment decision.

Hanmi Science, Megazone to advance Pharma AI transformation. AI Summary South Korea's Hanmi Science, the holding company of Hanmi Group, has entered into a partnership with Megazone to advance AI transformation (AX) across the pharmaceutical and healthcare industries. The companies announced the agreement on 31st August 2026, following the signing of a memorandum of understanding (MOU) at Hanmi Group's headquarters in Seoul's Songpa District. The agreement focuses on AX-based operational innovation and was signed in the presence of Hanmi Science CEO Kim Jae-kyo, President Lim Jong-hoon, Megazone Cloud Chairman Lee Joo-wan, and Megazone CEO Jang Ji-hwang. The partnership will bring together Hanmi Science's pharmaceutical and healthcare industry expertise and Megazone's AI and cloud technology capabilities. Rather than relying only on generic AI tools, the companies will work on services designed specifically for the operational characteristics and regulatory environment of the pharmaceutical and healthcare sectors. The initiative is intended to accelerate digital innovation throughout Hanmi Group and support a broader AI transformation approach across its operations. Megazone currently operates businesses covering AI, cloud, cybersecurity, and digital marketing through 33 domestic and international affiliates, including Megazone Cloud. Its local footholds extend across nine countries, including the United States, Japan, China, and Vietnam. Three areas set for joint development. The companies have outlined three main areas for cooperation: * These include identifying AX-based operational innovation initiatives * Strengthening digital transformation capabilities, and jointly pursuing new AI and digital innovation projects * Forming a working-level consultative body to develop specific initiatives and execution plans, with the companies intending to gradually broaden the scope of their cooperation Hanmi Science has already been working to establish an AI adoption culture throughout Hanmi Group. The company recently launched the "Hanmi AI Boost Program," covering all affiliates, including Hanmi Pharmaceutical, with the objective of identifying operational innovation use cases. The agreement with Megazone expands that internal effort by bringing in an external specialist firm. Hanmi Science CEO Kim Jae-kyo said, "Through this agreement, we will expand Hanmi Group's AX-based operational innovation and build a digital work environment that enables employees to work more efficiently." Megazone CEO Jang Ji-hwang said, "We will combine Hanmi Science's pharmaceutical and healthcare expertise with Megazone's cloud and AI-based operational innovation capabilities to create business models that generate new value," adding, "We will build a business model that delivers tangible results by combining industry understanding with AI technology." AI adoption expands across Pharma and bio. AI adoption is expanding across the pharmaceutical and bio industries, covering areas from new drug development and clinical trial design to manufacturing process optimization and sales and marketing efficiency. Major South Korean pharmaceutical companies are likewise moving faster on digital transformation, either by creating in-house AI organizations or by working with external technology firms. Against this backdrop, Hanmi Group's agreement with Megazone represents a strategic response to the industry's growing focus on AI transformation and digital innovation. The pharmaceutical industry rarely announces its most significant shifts loudly. The signals are there - if you know where to look. The Pharma Advancement briefing is how the sector's most informed professionals stay ahead of those signals - covering drug development, regulatory affairs, manufacturing, and market access across every major region. * The stories pharmaceutical professionals will be discussing tomorrow, in your inbox today * Analysis that goes beyond the headline - written for readers who already understand the industry * The briefing that the sector's most informed professionals open first